Patten & Patten Inc. TN decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,020 shares of the medical device company’s stock after selling 3,505 shares during the quarter. Patten & Patten Inc. TN’s holdings in DexCom were worth $2,864,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of the company. Cerebellum GP LLC purchased a new stake in DexCom in the second quarter worth approximately $171,000. Cibc Bank USA purchased a new stake in DexCom in the third quarter worth approximately $268,000. Clinton Group Inc. purchased a new stake in DexCom in the second quarter worth approximately $201,000. Bank Pictet & Cie Asia Ltd. purchased a new stake in DexCom in the second quarter worth approximately $218,000. Finally, Accredited Investors Inc. purchased a new stake in DexCom in the second quarter worth approximately $225,000.
Several brokerages recently issued reports on DXCM. Morgan Stanley raised their target price on shares of DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a report on Thursday, October 11th. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Northland Securities upgraded shares of DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Robert W. Baird increased their price target on shares of DexCom from $140.00 to $160.00 and gave the stock a “positive” rating in a research report on Thursday, August 23rd. Finally, Stephens increased their price target on shares of DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Thursday, August 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $123.13.
DXCM traded down $0.58 during trading on Wednesday, hitting $132.62. The company’s stock had a trading volume of 41,843 shares, compared to its average volume of 1,148,873. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69. DexCom, Inc. has a one year low of $43.74 and a one year high of $148.56. The company has a market capitalization of $12.64 billion, a PE ratio of -230.95 and a beta of 0.47.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $242.50 million for the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The company’s revenue was up 42.1% on a year-over-year basis. During the same period last year, the firm earned ($0.16) EPS. Equities analysts forecast that DexCom, Inc. will post -0.47 earnings per share for the current fiscal year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.